GlassScriptPhysician profile
Patricia V Chandler
NPI 1477714632
$4,313.54
in general payments reported to CMS, 2019-2025
23 companies · $817 in 2025
The $817 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $530 · 2020: $347 · 2021: $577 · 2022: $919 · 2023: $696 · 2024: $426 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,923 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,922.88 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $952.76 | 2019-2025 | Aplenzin, Wellbutrin |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $778.35 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $456.53 | 2019-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $343.56 | 2019-2024 | Spravato |
| Allergan, INC. | $312.51 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $209.49 | 2019-2025 | Rexulti |
| Abbvie INC. | $199.59 | 2021-2024 | Vraylar |
| Lundbeck LLC | $191.37 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $159.83 | 2022-2025 | Auvelity, Sunosi |
| Sunovion Pharmaceuticals INC. | $144.67 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $141.66 | 2022-2025 | Hetlioz, Fanapt |
| Tris Pharma INC | $72.49 | 2019-2025 | Dyanavel Xr |
| Eisai INC. | $71.66 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $52.20 | 2022-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $45.75 | 2020-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $37.01 | 2021-2022 | |
| Alfasigma USA, INC. | $27.97 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $26.91 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $25.66 | 2019 | |
| Ironshore Pharmaceuticals INC. | $19.85 | 2019 | |
| Noven Therapeutics, LLC | $16.13 | 2024 | Secuado, Xelstrym |
| Supernus Pharmaceuticals, INC. | $13.84 | 2022 | |
| Vertical Pharmaceuticals, LLC | $13.75 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Chandler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.